Opportunity Information: Apply for RFA DA 24 007
The Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1 - Clinical Trial Not Allowed) is a National Institutes of Health (NIH) funding opportunity designed to pull exceptional early-stage investigators into the substance use disorders (SUD) research space, specifically on the chemistry, pharmacology, and drug discovery side. The intent is to back bold, high-impact ideas from researchers who are still early in their independent careers and may not yet have the kind of extensive preliminary data typically expected for an R01. In other words, the program is meant to be a launchpad for talented scientists with strong potential to become future leaders, giving them room to pursue ambitious, potentially transformative research directions that could reshape how the field approaches SUD therapeutics.
The scientific focus is on innovative and forward-looking work that advances the chemical and pharmacological understanding of substance use disorders and accelerates the discovery or optimization of therapeutic strategies. The announcement highlights how the field has recently gained powerful new methods and technologies for identifying novel biological targets, mechanisms, and pathways relevant to addiction and related disorders. It also points to progress in developing chemical probes and optimized compounds that can serve as starting points for new medications. This grant is positioned to help investigators who already have expertise in emerging chemical biology, pharmacology, and drug discovery technologies apply those tools creatively to SUD problems, such as discovering new targets, clarifying mechanisms of drug action or addiction biology, creating or refining compounds, and developing advanced probes that open up new therapeutic possibilities.
As indicated by the designation "Clinical Trial Not Allowed," this opportunity is not intended to support clinical trials. The supported work should stay on the preclinical and mechanistic side of the spectrum, emphasizing chemistry and pharmacology approaches rather than human intervention studies. Applicants should align proposed aims to this boundary, focusing on foundational discoveries, tool and compound development, target validation, mechanistic pharmacology, and other non-clinical research that can eventually inform therapeutic development.
Administratively, this is a discretionary grant opportunity under NIH. The funding opportunity number is RFA-DA-24-007, and it falls under the Education and Health activity category, CFDA number 93.279. The original closing date listed is 2025-08-07. The award ceiling shown is 300,000 (as provided in the source information). The listing also notes "ExpectedAwards:" but does not provide a number in the supplied text.
Eligibility is broad and includes many common U.S. applicant organization types, such as public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city or township, special district governments), as well as independent school districts and public housing authorities/Indian housing authorities. It also includes Native American tribal governments (federally recognized) and Native American tribal organizations (other than federally recognized tribal governments). In addition, the opportunity explicitly calls out a range of other eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). This broad eligibility language signals an emphasis on attracting top talent from many institutional settings, including institutions serving populations historically underrepresented in biomedical research.
Overall, the program is best understood as a high-potential, early-career catalyst for researchers bringing cutting-edge chemistry and pharmacology approaches to substance use disorders. It prioritizes creativity, innovation, and the likelihood of major impact over a long track record of preliminary results, with the larger goal of speeding new mechanistic insights and therapeutic leads that could eventually improve prevention and treatment options for SUD.Apply for RFA DA 24 007
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
- This funding opportunity was created on 2022-10-20.
- Applicants must submit their applications by 2025-08-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Education, Health
Next opportunity: Population Pharmacokinetic Modeling of Systemic Pharmacokinetic Data to Inform Bioequivalence in Regional Lung Exposure (U01) Clinical Trial Not Allowed
Previous opportunity: HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 24 007
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 24 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) Apply for PAR 23 021 Funding Number: PAR 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) Apply for PAR 22 249 Funding Number: PAR 22 249 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed) Apply for PAR 22 239 Funding Number: PAR 22 239 Agency: National Institutes of Health Category: Education, Health Funding Amount: $375,000 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed) Apply for RFA CA 23 018 Funding Number: RFA CA 23 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed) Apply for PAR 23 041 Funding Number: PAR 23 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed) Apply for RFA CA 23 019 Funding Number: RFA CA 23 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed) Apply for RFA DA 24 003 Funding Number: RFA DA 24 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Targeting Inflammasomes in Substance Abuse and HIV (R21 Clinical Trial Not Allowed) Apply for RFA DA 24 004 Funding Number: RFA DA 24 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Investigating the Effects of Addictive Substances on Brain Developmental Trajectories Using Innovative Scalable Methods for Quantification of Cell Identity, Lineage and Connectivity (R01 - Clinical Trial Not Allowed) Apply for RFA DA 23 036 Funding Number: RFA DA 23 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Transformative Educational Advancement and Mentoring Network (TEAM) (R25 Clinical Trial Not Allowed) Apply for RFA CA 23 013 Funding Number: RFA CA 23 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional) Apply for RFA DA 23 059 Funding Number: RFA DA 23 059 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional) Apply for RFA DA 23 060 Funding Number: RFA DA 23 060 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,500,000 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 24 002 Funding Number: RFA DA 24 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required) Apply for RFA CA 23 020 Funding Number: RFA CA 23 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required) Apply for RFA CA 23 021 Funding Number: RFA CA 23 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required) Apply for RFA CA 23 022 Funding Number: RFA CA 23 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed) Apply for PAR 23 052 Funding Number: PAR 23 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed) Apply for PAR 23 051 Funding Number: PAR 23 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Apply for RFA CA 23 004 Funding Number: RFA CA 23 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 23 003 Funding Number: RFA CA 23 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 24 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.